PMID- 36253246
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230325
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 55
IP  - 3
DP  - 2023 Mar
TI  - Effects of prolonged proton pump inhibitor treatment on nutritional status and 
      respiratory infection risk in cystic fibrosis: A matched cohort study.
PG  - 360-365
LID - S1590-8658(22)00694-6 [pii]
LID - 10.1016/j.dld.2022.09.005 [doi]
AB  - BACKGROUND: Evidence on the effectiveness of proton pump inhibitors (PPI) as 
      adjuvant therapy to improve maldigestion in people with cystic fibrosis (pwCF) is 
      limited and there is increasing concern on possible side effects. METHODS: We 
      conducted a matched cohort study based on paediatric and adult pwCF who received 
      PPI for >/=3 months. Treated patients were matched to a group of patients who never 
      received PPI using a nearest neighbour propensity score matching based on sex, 
      year of birth, CFTR genotype and pancreatic insufficiency. RESULTS: The study 
      included 160 pwCF: 80 treated and 80 untreated patients. Over a median follow-up 
      of 2 years, no significant differences in changes in BMI z-score were detected 
      between groups (adjusted mean difference: 0.06, 95% CI: -0.17-0.30). At baseline 
      25% (n = 20) of the treated patients and 22.5% (n = 18) of the untreated patients 
      had a positive culture for P. aeruginosa (Pa). At follow-up percentages of Pa 
      positive cultures increased to 47.5% (n = 38) in the treated group and to 26.3% 
      (n = 21) in the untreated group (adjusted mean difference: 23.1%, 95% CI: 
      10.8-35.3). CONCLUSIONS: Prolonged PPI therapy should be used cautiously in pwCF 
      since it may increase the risk of respiratory infection by Pa. In addition, such 
      treatment does not seem to improve nutritional status.
CI  - Copyright (c) 2022. Published by Elsevier Ltd.
FAU - Zazzeron, Laura
AU  - Zazzeron L
AD  - Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Via Commenda 9, Milano 20122, Italy.
FAU - Alicandro, Gianfranco
AU  - Alicandro G
AD  - Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Via Commenda 9, Milano 20122, Italy; Department of Pathophysiology 
      and Transplantation, University of Milan, Milano, Italy.
FAU - Dacco, Valeria
AU  - Dacco V
AD  - Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Via Commenda 9, Milano 20122, Italy.
FAU - Lanfranchi, Chiara
AU  - Lanfranchi C
AD  - Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Via Commenda 9, Milano 20122, Italy.
FAU - Bulfamante, Anna
AU  - Bulfamante A
AD  - Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Via Commenda 9, Milano 20122, Italy.
FAU - Sciarrabba, Calogero Sathya
AU  - Sciarrabba CS
AD  - Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Via Commenda 9, Milano 20122, Italy.
FAU - Corti, Fabiola
AU  - Corti F
AD  - Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Via Commenda 9, Milano 20122, Italy.
FAU - Colombo, Carla
AU  - Colombo C
AD  - Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
      Policlinico, Via Commenda 9, Milano 20122, Italy; Department of Pathophysiology 
      and Transplantation, University of Milan, Milano, Italy. Electronic address: 
      carla.colombo@unimi.it.
LA  - eng
PT  - Journal Article
DEP - 20221014
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Child
MH  - *Proton Pump Inhibitors/therapeutic use
MH  - *Cystic Fibrosis/genetics
MH  - Cohort Studies
MH  - Nutritional Status
OTO - NOTNLM
OT  - Cystic fibrosis
OT  - Nutritional status
OT  - Proton pump inhibitors
OT  - Respiratory infections
COIS- Declaration of Competing Interest The authors declare no conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/10/17 22:05
PHST- 2022/03/22 00:00 [received]
PHST- 2022/08/11 00:00 [revised]
PHST- 2022/09/03 00:00 [accepted]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/10/17 22:05 [entrez]
AID - S1590-8658(22)00694-6 [pii]
AID - 10.1016/j.dld.2022.09.005 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2023 Mar;55(3):360-365. doi: 10.1016/j.dld.2022.09.005. Epub 2022 
      Oct 14.